Skip to main content
Equibles
PCRX logo

PCRX · Pacira BioSciences, Inc. · Metrics

Track PCRX — free

Use PCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$36.38 -0.02 (-0.05%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.45B
Shares
39.86M
Volume · Oct 28 378.84K Avg daily vol (3M) 1.24M

PCRX metrics

108 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$36.40
Market cap
$1.45B

Price action

20 metrics
Price change (1W)
+0.1%
Price change (30D)
+43.4%
Price change (3M)
+35.8%
Price change (6M)
+43.3%
Price change (YTD)
+40.6%
Price change (1Y)
+70.7%
Trailing year
Price change (5Y)
-29.5%
52-week high
$36.42
52-week low
$19.16
Change from 52-week high
-0.1%
Change from 52-week low
+90.0%
Annualized volatility
57.4%
Annualized volatility (3M)
93.7%
Beta
0.1
RSI (14D)
83.4
Price vs SMA 50
+28.5%
Price vs SMA 200
+47.8%
Avg volume (3M)
1.24M
Relative volume
0.4
Average dollar volume
$39.65M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
39.86M

Valuation

12 metrics
P / E (TTM)
101.1
Trailing earnings · reciprocal yield 1.0%
PEG ratio
—
EV / revenue
2.1×
reciprocal yield 47.8%
EV / EBITDA
14.9×
reciprocal yield 6.7%
EV / EBIT
78.6×
reciprocal yield 1.3%
P / sales
1.9×
reciprocal yield 51.5%
P / book
2.2
reciprocal yield 46.3%
FCF yield
12.4%
TTM · current market cap
Buyback yield
10.2%
P / FCF
8.1
reciprocal yield 12.4%
P / operating cash flow
7.7
reciprocal yield 12.9%
Earnings yield
1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
42.0×
reciprocal yield 2.4%
P / E historical average (5Y)
42.0×
reciprocal yield 2.4%
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.5%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 56.5%
EV / EBIT historical average (3Y)
33.5×
reciprocal yield 3.0%
EV / EBIT historical average (5Y)
33.5×
reciprocal yield 3.0%
EV / EBITDA historical average (3Y)
23.3×
reciprocal yield 4.3%
EV / EBITDA historical average (5Y)
23.3×
reciprocal yield 4.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
10.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
79.2%
Operating margin
2.7%
Trailing 12 months
Net margin
2.0%
Gross profit (TTM)
$591.01M
Operating profit (TTM)
$19.87M
Net income (TTM)
$14.64M
Trailing 12 months
Diluted EPS (TTM)
$0.36
FCF margin
24.1%
Effective tax rate
17.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$17.65
Gross profit per diluted share (TTM)
$13.97
Operating profit per diluted share (TTM)
$0.47
EBITDA per diluted share (TTM)
$2.49
Net income per diluted share (TTM)
$0.35
Operating cash flow per diluted share (TTM)
$4.42
Free cash flow per diluted share (TTM)
$4.23
Capital expenditures per diluted share (TTM)
$0.19
R&D per diluted share (TTM)
$2.88
Stock compensation per diluted share (TTM)
$1.32
Book value per share
$16.86

Growth

11 metrics
Revenue growth YoY
+6.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$746.16M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-11.3%
Year over year · fewer shares
Revenue CAGR (3Y)
+2.9%
Revenue CAGR (5Y)
+11.1%
EPS CAGR (3Y)
-22.2%
EPS CAGR (5Y)
-45.5%
FCF CAGR (3Y)
+5.9%
FCF CAGR (5Y)
+28.4%

Quality

14 metrics
Return on equity
2.2%
Return on assets
1.2%
Debt / equity
0.5
Current ratio
5.0
EBITDA (TTM)
$105.03M
Free cash flow (TTM)
$179.51M
Quick ratio
3.9
Interest coverage
1.3
Net debt / EBITDA
1.1
Return on invested capital
2.1%
Trailing 12 months
Net cash
−$112.09M
Latest balance sheet
Cash & equivalents
$205.88M
Total assets
$1.24B
Total debt
$363.12M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$187.66M
Capital expenditures (TTM)
$8.15M
R&D (TTM)
$122.08M
SG&A (TTM)
$379.16M
Stock compensation (TTM)
$55.97M
R&D / revenue
16.4%
Stock compensation / revenue
7.5%

Ownership (13F)

9 metrics
13F filers
255
13F filer change QoQ
+13
Institutional ownership
109.9%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.1%
Holder tenure
15.4
Price vs estimated holder cost
+4.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
30.7%

Short interest

3 metrics
Short interest
10.7%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$288,539
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1396814 CUSIP 695127100 13F (30d) 51 filings 50 filers Visit website Investor relations